Genmab A/S Files 6-K for S-8 Incorporation
Ticker: GNMSF · Form: 6-K · Filed: Jun 20, 2024 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Jun 20, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, procedural, registration-statement
TL;DR
Genmab filed a 6-K, mostly procedural stuff for stock plans, no new financials.
AI Summary
Genmab A/S filed a Form 6-K on June 20, 2024, to be incorporated by reference into its existing S-8 registration statements. This filing does not contain new financial information but serves to update or supplement previously filed documents.
Why It Matters
This filing is procedural and ensures that Genmab's registration statements remain current with the SEC, which is important for ongoing stock-based compensation plans.
Risk Assessment
Risk Level: low — The filing is a routine procedural update and does not contain new material financial or operational information that would typically impact stock price.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 0001558370-24-009333 (filing_id) — Accession Number
- 20240620 (date) — Filing Date
- Form S-8 (filing_type) — Incorporated by reference into
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The purpose of this Form 6-K is to be incorporated by reference into Genmab A/S's existing registration statements on Form S-8 (File Nos. 333-232693, 333-253519, 333-262970 and 333-277273).
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on June 20, 2024.
Does this filing contain new financial results for Genmab A/S?
No, this filing is procedural and serves to be incorporated by reference into existing registration statements; it does not appear to contain new financial results.
Which specific registration statements will this 6-K be incorporated into?
This 6-K will be incorporated into Genmab A/S's registration statements on Form S-8, specifically File Numbers 333-232693, 333-253519, 333-262970, and 333-277273.
What is the principal executive office address for Genmab A/S as listed in the filing?
The address of the principal executive offices for Genmab A/S is Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 210 words · 1 min read · ~1 pages · Grade level 13.9 · Accepted 2024-06-20 10:54:13
Filing Documents
- tmb-20240620x6k.htm (6-K) — 19KB
- tmb-20240620xex3d1.htm (EX-3.1) — 277KB
- 0001558370-24-009333.txt ( ) — 297KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF JUNE 2024 COMMISSION FILE NUMBER 001-38976 Genmab A/S (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970 and 333-277273 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GENMAB A/S BY: /s/ Anthony Pagano Name: Anthony Pagano Title: Executive Vice President & Chief Financial Officer DATE: JUNE 20, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 3.1 Articles of Association